Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$7.41 USD
-0.80 (-9.74%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $7.44 +0.03 (0.40%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CYCC 7.41 -0.80(-9.74%)
Will CYCC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CYCC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYCC
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Misses Revenue Estimates
CYCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Surpass Estimates
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for CYCC
Why Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT ...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket